Metformin + GLP-1 receptor agonists
1 paper3 findings
- 1 lab in 2 countries
- Humans1
Associations
3Alzheimer's disease
downin humans1HR 0.46
1 study
Alzheimer's disease
downin humans1HR 0.46
Metformin + GLP-1 receptor agonists lower the risk of Alzheimer's disease in humans (HR 0.46, 95% CI 0.31-0.70).
Humanstype 2 diabetes, versus metformin only
PloS one24 Aug 2026
Mild cognitive disorder
downin humans1HR 0.79
1 study
Mild cognitive disorder
downin humans1HR 0.79
Metformin + GLP-1 receptor agonists lower the risk of mild cognitive disorder in humans (HR 0.79, 95% CI 0.66-0.95).
Humanstype 2 diabetes, versus metformin only
PloS one24 Aug 2026
Vascular dementia
downin humans1HR 0.46
1 study
Vascular dementia
downin humans1HR 0.46
Metformin + GLP-1 receptor agonists lower the risk of vascular dementia in humans (HR 0.46, 95% CI 0.37-0.57).
Humanstype 2 diabetes, versus metformin only
PloS one24 Aug 2026